A 2016 panorama of Helicobacter pylori infection: Key messages for clinicians

Panminerva Medica

Volumn 58, Issue 4, 2016, Pages 304-317

  Pellicano, Rinaldo ^a   Ribaldone, Davide G ^a   Fagoonee, Sharmila ^b   Astegiano, Marco ^a   Saracco, Giorgio M ^a,c   Mégraud, Francis ^d  

^a Molinette SgaS Hospital   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Helicobacter pylori; Lymphoma; Peptic ulcer; Stomach neoplasms; Therapy; Vaccines

Indexed keywords

ANTIINFECTIVE AGENT;

COMBINATION DRUG THERAPY; COMPLICATION; DYSPEPSIA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; LYMPHOMA, B-CELL, MARGINAL ZONE; PEPTIC ULCER; RECURRENT DISEASE; STOMACH NEOPLASMS;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; DYSPEPSIA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; PEPTIC ULCER; RECURRENCE; STOMACH NEOPLASMS;

EID: 84994786385     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
2. Pellicano R, Rizzetto M, Graham DY. Evolving challenges of Helicobacter pylori. Minerva Gastroenterol Dietol 2011;57:333-4.
3. Rosso C, Fagoonee S, Altruda F, Pellicano R. Update on colonization, survival and antibiotic resistance of Helicobacter pylori at the molecular level. Minerva Biotec 2015;27:149-57.
4. Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012;17(Suppl 1):1-8.
5. McColl KE. Clinical practice Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
6. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol 2003;65:103-31.
7. el-Omar EM, Penman ID, Ardill JES, Chittajallu RS, Howie C, Mc-Coll KEL. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681-91.
8. Gillen D, el-Omar EM, Wirz AA, Ardill JES, McColl KEL. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998;114:50-7.
9. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet 2009;374:1449-61.
10. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996;110:1244-52.
11. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-Analysis. Lancet 2002;359:14-22.
12. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological association technical review: evaluation of dyspepsia. Gastroenterology 2005;129:1756-80.
13. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology 2016;150:1380-92.
14. Malfertheiner P, Mégraud F, O'Morain C, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection: The Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
15. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.
16. Zullo A, Hassan C, De Francesco V, Repici A, Manta R, Tomao S, et al. Helicobacter pylori and functional dyspepsia: An unsolved issue? World J Gastroenterol 2014;20:8957-63.
17. Zagari RM, Law GR, Fuccio L, Cennamo V, Gilthorpe MS, Forman D, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: An endoscopic study. Gastroenterology 2010;138:1302-11.
18. Tan AC, Hartog GD, Mulder CJ. Eradication of Helicobacter pylori does not decrease the long-Term use of acid-suppressive medication. Aliment Pharmacol Ther 1999;13:1519-22.
19. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
20. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012;13:607-15.
21. Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-Analysis. Gastroenterology 2016;150:1113-24.
22. Machado AM, Figueiredo C, Touati E, Máximo V, Sousa S, Michel V, et al. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res 2009;15:2995-3002.
23. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 2004;157:301-10.
24. Sakaki N, Kozawa H, Egawa N, Tu Y, Sanaka M. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther 2002;16(Suppl 2):198-203.
25. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. NEJM 2001;345:784-9.
26. Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, et al. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population. Arch Intern Med 2000;160:1962-8.
27. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
28. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-Analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
29. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: A combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001;49: 347-53.
30. Rugge M, Busatto G, Cassaro M, Shiao YH, Russo V, Leandro G, et al. Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer 1999;85:2506-11.
31. Webb PM, Crabtree JE, Forman D. Gastric cancer, cytotoxin-Associated gene A-positive Helicobacter pylori, and serum pepsinogens: An international study: The Eurogast Study Group. Gastroenterology 1999; 116:269-76.
32. Fagoonee S, Li H, Zhang H, Altruda F, Pellicano R. Gastric cancer as a stem-cell disease: data and hypotheses. Panminerva Med 2014;56:289-300.
33. Bessède E, Dubus P, Mégraud F, Varon C. Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene 2015;34:2547-55.
34. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori and gastric lymphoma. NEJM 1994;330:1267-71.
35. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 2005;128:1579-1605.
36. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-7.
37. Adriani A, Fagoonee S, De Angelis C, Altruda F, Pellicano R. Helicobacter pylori infection and dementia: can actual data reinforce the hypothesis of a causal association? Panminerva Med 2014;56:195-9.
38. Moosazadeh M, Shahbazi N, Mahmoodi G, Abdi Joubari H, Mahdavi SA, Babania Rostam FZ, et al. The relationship between the prevalence of Helicobacter pylori and serum levels of vitamin B12 in women 10-49 years. Minerva Gastroenterol Dietol 2015;61:131-5.
39. Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter 2015;20(Suppl 1):40-6.
40. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter 2009;14(Suppl 1):58-68.
41. C over TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009;136:1863-73.
42. Ribaldone DG, Fagoonee S, Colombini J, Saracco G, Astegiano M, Pellicano R. Helicobacter pylori infection and asthma: is there a direct or an inverse association? A meta-Analysis. World J Meta-Anal 2016;4:63-8.
43. Midolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori: urease tests. Gastroenterol Clin North Am 2000;29:871-8.
44. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001;48:287-9.
45. Mégraud F, O'Morain C, Malfertheiner P. Working Party of the European Helicobacter pylori Study Group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997;41(Suppl 2):S1-S23.
46. Shirin H, Levine A, Shevah O, Shabat-Sehayek V, Aeed H, Wardi J, et al. Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion 2005;71:208-12.
47. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: A systematic review. Helicobacter 2004;9:347-68.
48. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A metaanalysis. Am J Gastroenterol 1996;91:1138-44.
49. American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointestinal Endoscopy 2010;71:663-8.
50. Racz I, Bircher K, Karasz T, Németh A. The influence of Helicobacter pylori infection on early rebleeding rate in patients with peptic ulcer bleeding. Endoscopy 2004;36:461-2.
51. McAlindon ME, Taylor JS, Ryder SD. The long-Term management of patients with bleeding duodenal ulcers. Aliment Pharmacol Ther 1997;11:505-10.
52. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13.
53. Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, et al. Pharmacological regimens for eradication of Helicobacter pylori: An overview of systematic reviews and network meta-Analysis. BMC Gastroenterol 2016;16:80.
54. Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: A critical review. J Clin Gastroenterol 2010;44:313-25.
55. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.
56. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
57. Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis 2015;47:903-12.
58. Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
59. Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and antibiotic resistance, a continuing and intractable problem. Helicobacter 2016 [Epub ahead of print].
60. Zanasi A, Lecchi M, Mazzolini M, Mastroroberto M, Nardi E, Morselli-Labate A. Observational prospective study comparing mucoactive and antibiotic treament in the management of acute cough from upper respiratory tract infections. Minerva Med 2015;106:239-46.
61. Hulten K, Gibreel A, Skold O, Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-Treated patients. Antimicrob Agents Chemother 1997;41:2550-3.
62. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
63. Mégraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
64. De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, et al. Primary clarithromycin resistance in Helicobacter pylori: The multicentric Italian clarithromycin resistance observational (MICRO) Study. J Gastrointest Liver Dis 2011;20:235-9.
65. Tursi A, Elisei W, Giorgeti G, Picchio M, Brandimarte G. Decreasing efficay of the standard seven-day triple therapy contining amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy; a 10-year follow-up study. Panminerva Med 2014;56:57-61.
66. Ribaldone DG, Fagoonee S, Astegiano M, Saracco G, Pellicano R. Efficacy of amoxycillin and clarithromycin based triple therapy for Helicobacter pylori eradication: A 10 year trend in Turin, Italy. Panminerva Med 2015;57:145-6.
67. Ducournau A, Bénéjat L, Sifré E, Bessède E, Lehours P, Mégraud F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect 2016;22:715-8.
68. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-Analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
69. Villoria A. Acid-related diseases: Are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol 2008;31:546-7.
70. Li B-Z, Threapleton DE, Wang J-Y, Xu J-M, Yuan J-Q, Zhang C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: Systematic review and network meta-Analysis. BMJ 2015;351.h4052.
71. Hsu P-I, Lin P-C, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systematic review and meta-Analysis. World J Gastroenterol 2015;21:12954-62.
72. Braden B. The best and worst treatments for Helicobacter pylori. BMJ 2015;351:h4146.
73. Liou J-M, Chen C-C, Lee Y-C, Chang C-Y, Wu J-Y, Bair M-J, et al. Systematic review with meta-Analysis: 10-or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;43:470-81.
74. Nyssen OP, McNicholl AG, Mégraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2016; Issue 6. Art. No.: CD009034. DOI:10.1002/14651858.
75. Vakil N, Mégraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
76. Mégraud F. Failed eradication for Helicobacter pylori. What should be done? Dig Dis 2016;34:505-9.
77. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomized, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
78. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014;40:171-7.
79. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012;35:209-221.
80. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-Analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015;41:1237-45.
81. Zou J, Dong J, Yu X. Meta-Analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009;14:97-107.
82. Sachdeva A, Nagpal J. Meta-Analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009;29:720-30.
83. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-Analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68.
84. Raymond J, Thiberge JM, Dauga C. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. Scand J Gastroenterol 2016;51:672-8.
85. Moya DA, Crissinger KD. Helicobacter pylori persistence in children: distinguishing inadequate treatment, resistant organisms, and reinfection. Curr Gastroenterol Rep 2012;14:236-42.
86. Niv Y. H pylori recurrence after successful eradication. World J Gastroenterol 2008;14:1477-8.
87. Zhang Y-Y, Xia HH-X, Zhuang Z-H, Zhong J. Review article: "true" re-infection of Helicobacter pylori after successful eradicationworldwide annual rates, risk factors and clinical implications. Aliment Pharmacol Ther 2008;29:145-60.
88. Ryu KH, Yi SY, Na YJ, Baik SJ, Yoon SJ, Jung HS, et al. Reinfection rate and endoscopic changes after successful eradication of Helicobacter pylori. World J Gastroenterol 2010;16:251-5.
89. Gisbert JP, Garcìa Arata I, Boixeda D, Barba M, Cantòn R, Plaza AG, et al. Role of partner's infection in reinfection after Helicobacter species eradication. Eur J Gastroenterol Hepatol 2002;14:865-71.
90. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116:804-12.
91. Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G, et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomized controlled vaccination with Ty21a-based Salmonella vaccines. Gut 2008;57:1065-72.
92. Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: A randomized, doubleblind, placebo-controlled, phase 3 trial. Lancet 2015;386:1457-64.
93. Sutton P. At last, vaccine-induced protection against Helicobacter pylori. Lancet 2015;386:1424-5.